We are Sorry, This Page doesn't Exist
Harmony Biosciences Expands It CNS-Focused Pipeline With Epilepsy Candidate, Q1 Earnings Beat Street View
Harmony Biosciences expands its late-stage CNS pipeline with the acquisition of Epygenix Therapeutics, bolstering its rare epilepsy offerings. Harmony's Q1 performance shows robust growth, with adjusted EPS surpassing expectations. read more.....»»
AstraZeneca admits its Covid vaccine can cause rare side effect in court documents for first time
AstraZeneca admits its Covid vaccine can cause rare side effect in court documents for first time.....»»
Dow Surges Over 100 Points; Domino"s Pizza Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Monday. Following the market opening Monday, the Dow traded up 0.36% to 38,375.82 while the NASDAQ rose 0.57% to 16,018.15. The S&P 500 also.....»»
AstraZeneca admits for first time in court documents its Covid vaccine can cause rare side effect
AstraZeneca admits for first time in court documents its Covid vaccine can cause rare side effect.....»»
AstraZeneca admits for first time its Covid vaccine can cause rare side effect
AstraZeneca admits for first time its Covid vaccine can cause rare side effect.....»»
Inspira CEO calls new $50M Deptford outpatient center "the model" as project pipeline speeds ahead
CEO Amy Mansue said the health system continues to make progress on the redevelopment of its Woodbury campus......»»
A Chinese ship remains the focus of the investigation into Baltic Sea gas pipeline damaged last year
A Chinese ship remains the focus of the investigation into Baltic Sea gas pipeline damaged last year.....»»
Roku Exceeds Q1 Earnings Expectations, Provides Upbeat Guidance
Roku reported quarterly losses of 35 cents per share which b.....»»
Western Digital Q3 Earnings: Revenue Beat, Higher ASP, Upbeat Q4 Guidance And More
Western Digital reported earnings of 63 cents per share and quarterly sales of $3.46 billion which beat the $3.36 billion analyst consensus estimate. "As evidenced by our excellent third quarter results, Western Digital continu.....»»
Roku Exceeds Q1 Earnings Expectations, Provides Upbeat Guidance
Roku, Inc. (NASDAQ:ROKU) reported its firs.....»»
"Reels, Messaging, and AI:" What Wall Street analysts expect from Meta as it gears up for first-quarter earnings
Wall Street is upbeat heading into Meta Platforms' first-quarter earnings, with analysts touting its leadership in ad spending and AI initiatives. Meta CEO Mark Zuckerberg.Josh Edelson/AFP via Getty Images Meta Platf.....»»
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow. Latest Ratings for INCY DateFirmActio.....»»
Insights Into Astrazeneca Q1: Wall Street Projections for Key Metrics
In its upcoming report, Astrazeneca (NYSE: AZ.....»»
Looking At AstraZeneca"s Recent Unusual Options Activity
read more.....»»
Montgomery County Commissioners delve into state of county, project pipeline
The Montgomery County Commissioners recently held a State of the County event to delve into strategies for 2024: infrastructure modernization, healthy community and ready workforce......»»
These Analysts Raise Their Forecasts On Charles Schwab Following Upbeat Earnings
Charles Schwab Corporation (NYSE: SCHW) reported better-than-expected first-quarter sales results on Monday. Charles Schwab reported a first-quarter 2024 adj.....»»
Dow Gains Over 100 Points; Bank of America Posts Upbeat Profit
U.S. stocks traded.....»»
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. read more.....»»
AstraZeneca"s Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
AstraZeneca's updated data from TOPAZ-1 Phase 3 trial of Imfinzi (durvalumab) in advanced biliary tract cancer patients. Unveiling long-term survival benefits and significant overall survival improvement. read more.....»»